Organ and Tissue Transplantation and Alternatives
- March 2015 •
- 196 pages •
- Report ID: 96592
The global market for organ and tissue transplantation products and devices reached $55.6 billion in 2014. This market is estimated to grow at a compound annual growth rate (CAGR) of 6.8% to reach $62.9 billion by 2015 and $88.1 billion by 2020.
This report provides:
An overview of the global markets for organ and tissue transplantation and alternatives.
Analyses of global market trends, with data from 2014, estimates for 2015 and projections of CAGR through 2020.
Detailed examination of procurement and preservation, solid organ transplantation, tissue transplantation, immunosuppressives and other pharmaceuticals, post-transplantation concerns, as well as alternatives to transplantation.
Coverage of post-transplant immunosuppression and monitoring methods and post-transplant drug regimens and patient and graft survival rates.
In-depth analysis of the market's dynamics, specifically growth drivers, inhibitors, and opportunities
Comprehensive profiles of major players in the industry.
SCOPE OF REPORT
This report offers forecasts, by product segment, from 2015 through 2020, including supporting analyses for projections. Product segments covered consist of the solid organ (e.g., kidneys, liver, heart-lung, pancreas, intestines) and the tissue transplantation (e.g., bone, skin, cornea, heart valve) markets, along with the pharmaceuticals that accompany each market.
Also included are experimental xenografts and artificial organs; tissue transplants; and cell transplants (e.g., bone marrow, cord blood, peripheral blood, islet cell). The report touches on the use of fetal cells, stem cells and altered cancer cells.
The arrangement of this report offers an overview of the key elements in the transplantation process: tissue typing, procurement and preservation, immunosuppressants for solid organ and tissue transplants and postoperative monitoring. International markets are discussed, and information is provided on industry structure and the regulatory environment.
Within each section are discussions of commercialization opportunities for each segment of the market. New or emerging devices, techniques and pharmaceuticals are highlighted.
Profiles of more than 50 leading companies involved with solid organ transplantation, tissue transplantation, and alternative technologies are included. The report provides information on company placement within the market and strategic analyses of the companies’ available and emerging products.
An appendix featuring various terms and processes used in transplantation is provided at the end of the report.
This report cites autologous products only in relation to their impact on the market for allografts. It does not include blood products, with the exception of peripheral and umbilical cord blood as a source of stem cells.